Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.

Cedric PobelEdouard AuclinDiego TeyssonneauBrigitte LaguerreMathilde CancelElouen BoughalemJohanna NoelPierre Emmanuel BrachetDenis MailletPhilippe BarthelemyCarole HelisseyConstance ThibaultStéphane Oudard

Published in: Cancer medicine (2021)

Patients with metastatic castration-resistant prostate cancer can be treated with Cabazitaxel after docetaxel and androgen receptor-targeted agent. This chemotherapy can be used multiple times with efficacy and manageable toxicity.

Keyphrases

locally advanced
squamous cell carcinoma
small cell lung cancer
oxidative stress
cancer therapy
radiation therapy
rectal cancer
drug delivery